These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Phase I study of spirogermanium given daily. Legha SS; Ajani JA; Bodey GP J Clin Oncol; 1983 May; 1(5):331-6. PubMed ID: 6668504 [TBL] [Abstract][Full Text] [Related]
25. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934). LoRusso P; Foster BJ; Poplin E; McCormick J; Kraut M; Flaherty L; Heilbrun LK; Valdivieso M; Baker L Clin Cancer Res; 1995 Dec; 1(12):1487-93. PubMed ID: 9815948 [TBL] [Abstract][Full Text] [Related]
26. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. McDonald AC; Vasey PA; Adams L; Walling J; Woodworth JR; Abrahams T; McCarthy S; Bailey NP; Siddiqui N; Lind MJ; Calvert AH; Twelves CJ; Cassidy J; Kaye SB Clin Cancer Res; 1998 Mar; 4(3):605-10. PubMed ID: 9533527 [TBL] [Abstract][Full Text] [Related]
27. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073 [TBL] [Abstract][Full Text] [Related]
28. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors. Supko JG; Balcerzak SP; Kraut EH Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671 [TBL] [Abstract][Full Text] [Related]
29. Phase I study of m-AMSA in patients with solid tumors and leukemias. Goldsmith MA; Bhardwaj S; Ohnuma T; Greenspan EM; Holland JF Cancer Clin Trials; 1980; 3(3):197-202. PubMed ID: 6893683 [TBL] [Abstract][Full Text] [Related]
30. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion. Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246 [TBL] [Abstract][Full Text] [Related]
31. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438 [TBL] [Abstract][Full Text] [Related]
32. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. Faivre S; Raymond E; Boige V; Gatineau M; Buthaut X; Rixe O; Bernareggi A; Camboni G; Armand JP Clin Cancer Res; 2001 Jan; 7(1):43-50. PubMed ID: 11205916 [TBL] [Abstract][Full Text] [Related]
33. A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors. Vokes EE; Goh BC; Bertucci D; Vogelzang NJ; Mani S; Ratain MJ Cancer; 1999 Aug; 86(3):528-32. PubMed ID: 10430263 [TBL] [Abstract][Full Text] [Related]
34. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion. Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185 [TBL] [Abstract][Full Text] [Related]
35. Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days. Dodion P; de Valeriola D; Crespeigne N; Peeters B; Wery F; van Berchem C; Piccart M; Tueni E; Joggi J; Kenis Y Eur J Cancer Clin Oncol; 1988 Jun; 24(6):1019-26. PubMed ID: 2970391 [TBL] [Abstract][Full Text] [Related]
36. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer. Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321 [TBL] [Abstract][Full Text] [Related]
37. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors. Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997 [TBL] [Abstract][Full Text] [Related]
38. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. Rowinsky EK; Johnson TR; Geyer CE; Hammond LA; Eckhardt SG; Drengler R; Smetzer L; Coyle J; Rizzo J; Schwartz G; Tolcher A; Von Hoff DD; De Jager RL J Clin Oncol; 2000 Sep; 18(17):3151-63. PubMed ID: 10963644 [TBL] [Abstract][Full Text] [Related]
39. A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors. Maltezos E; Amarantidis K; Trichas M; Vasiliadis M; Toromanidou M; Chatzaki E; Karayiannakis A; Tsaroucha A; Romanidis K; Kakolyris S Oncology; 2005; 69(6):463-9. PubMed ID: 16374040 [TBL] [Abstract][Full Text] [Related]
40. Prediction of hematologic toxicity of carboplatin by creatinine clearance rate. Taguchi J; Saijo N; Miura K; Shinkai T; Eguchi K; Sasaki Y; Tamura T; Sakurai M; Minato K; Fujiwara Y Jpn J Cancer Res; 1987 Sep; 78(9):977-82. PubMed ID: 3117753 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]